CN109762016B - A kind of alkynylphosphonic acid bisaryltin complex with antitumor activity and its application - Google Patents

A kind of alkynylphosphonic acid bisaryltin complex with antitumor activity and its application Download PDF

Info

Publication number
CN109762016B
CN109762016B CN201910133828.7A CN201910133828A CN109762016B CN 109762016 B CN109762016 B CN 109762016B CN 201910133828 A CN201910133828 A CN 201910133828A CN 109762016 B CN109762016 B CN 109762016B
Authority
CN
China
Prior art keywords
complex
bisaryltin
activity
cancer
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910133828.7A
Other languages
Chinese (zh)
Other versions
CN109762016A (en
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Xinke Pharmaceutical Co ltd
Original Assignee
Chengdu Xinke Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Xinke Pharmaceutical Co ltd filed Critical Chengdu Xinke Pharmaceutical Co ltd
Priority to CN201910133828.7A priority Critical patent/CN109762016B/en
Publication of CN109762016A publication Critical patent/CN109762016A/en
Application granted granted Critical
Publication of CN109762016B publication Critical patent/CN109762016B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种具有抗肿瘤活性的炔基膦酸双芳基锡配合物及其应用,其具有以下结构:(Ar3SnO)2P(O)R;其中,Ar为任选取代的苯基;

Figure DDA0001976280990000011
且R2为任选取代的烷基、芳基、杂芳基。本申请首次通过结构修饰筛选出了新的具有抗癌活性的炔基膦酸双芳基锡配合物,并对其活性进行测试,其体现出比顺铂强的活性,是潜在的临床抗肿瘤药物。The present invention relates to an alkynylphosphonic acid bisaryltin complex with antitumor activity and application thereof, which has the following structure: (Ar 3 SnO) 2 P(O)R; wherein, Ar is an optionally substituted benzene base;
Figure DDA0001976280990000011
and R2 is optionally substituted alkyl, aryl, heteroaryl. In this application, a new alkynylphosphonic acid bisaryltin complex with anticancer activity has been screened for the first time through structural modification, and its activity has been tested. It shows stronger activity than cisplatin and is a potential clinical antitumor drug.

Description

Alkynyl phosphonic acid diaryl tin complex with anti-tumor activity and application thereof
Technical Field
The invention relates to an alkynyl phosphonic acid diaryl tin complex with anti-tumor activity, belonging to the field of pharmaceutical chemistry.
Background
The phosphonic (phosphoric) acid derivative of alkyl tin has stronger biological activities of killing insects, killing bacteria, weeding and the like, and is greatly concerned by people. The research on the hydrocarbyl tin complex of alkynyl phosphonic acid has been reported in documents (synthesis and properties of Wangshanhua, O-triphenyl tin unsaturated hydrocarbyl phosphonic acid, chemical reagent, 23(3), 141-143; synthesis and structural characterization of Yi Han Dong, O-tributyl tin alkynyl or alkenyl phosphonic acid, chemical reagent, 22(6), 133-334; synthesis and structural characterization of Yi Han Dong, phenyl tin alkynyl phosphonate, chemical notification, 7, 44-46; synthesis and structural characterization of Yi Han Dong, tribenzyl tin (IV) alkynyl (alkenyl) phosphonic acid derivative, inorganic chemical report, 1,127-130), but these documents mostly focus on the synthesis and structural research stage, and have less research on pharmacological activity, and mostly test the activity of sterilization, acaricidal and the like, and have less research on the antitumor activity of the complex.
Based on the consideration that tin complexes also have certain antitumor activity (CN102775449A and CN102424639A), in order to search for new anticancer drugs, proper structural improvement and screening are carried out on the existing dialkyl tin complexes of alkynyl phosphonic acid on the basis of the existing documents. Preliminary tests on biological activity show that the bisaryl tin complex of the alkynyl phosphonic acid has certain anticancer activity, and especially, the complexes with a plurality of specific structures show excellent activity.
Disclosure of Invention
On the basis of fully researching the prior art, the application screens a novel alkyl diaryl tin complex of alkynyl phosphonic acid with anticancer activity, thereby providing a novel antitumor candidate compound.
In order to achieve the purpose, the technical scheme of the invention is realized as follows:
an alkynylphosphonic acid bisaryl tin complex with anti-tumor activity, characterized by having the following structure: (Ar)3SnO)2P (O) R; wherein Ar is optionally substituted phenyl;
Figure BDA0001976280980000011
and R is2Is optionally substituted alkyl, aryl, heteroaryl.
The alkynyl phosphonic acid diaryl tin complex is characterized in that: ar is phenyl, halogen or alkyl or alkoxy or nitro substituted phenyl; r2Is optionally substituted C1-C6 alkyl, C6-C10 aryl, C6-C10 heteroaryl.
The alkynyl phosphonic acid diaryl tin complex is characterized in that: ar is phenyl, 4-chlorphenyl, 2, 4-dichlorophenyl, preferably 2, 4-dichlorophenyl; r2Is a butyl group, preferably a tert-butyl group.
The alkynyl phosphonic acid diaryl tin complex is used for preparing anti-cancer drugs, wherein the cancers comprise cervical cancer, breast cancer, lung adenocarcinoma, liver cancer, prostatic cancer, colon cancer and the like.
The complex of the invention has the following beneficial effects:
the invention carries out structural modification on the alkynyl phosphonic acid diaryl tin complex, screens out a compound with anticancer activity, embodies stronger activity than cisplatin, and is a potential clinical antitumor drug.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the following detailed description of representative embodiments of the present invention is given without being limited thereto.
EXAMPLE 1 Synthesis of Compound 1
The structural formula of the product is:
Figure BDA0001976280980000021
adding 3mmol of tris (2, 4-dichlorophenyl) tin chloride and 35mL of anhydrous methanol into a 100mL round-bottom flask, stirring, completely dissolving, adding 1.5mmol of tert-butyl ethynyl disodium phosphate, stirring under reflux for reacting for 6 hours, cooling, filtering, concentrating the filtrate under reduced pressure, adding a proper amount of petroleum ether, filtering, and concentrating in vacuum to obtain the product with the yield of 78%.
Elemental analysis data: anal, calcd, for C42H27Cl12O3PSn2(%): c39.61, H2.14, Sn 18.64; found (%): c39.68, H2.29, Sn 18.73. Nuclear magnetic hydrogen spectrum data:1H NMR/δ1.34-1.68(9H),7.13-7.48(18H)。
example 2
Adding 3.5mmol of tris (2, 4-dichlorophenyl) tin chloride and 35mL of anhydrous methanol into a 100mL round-bottom flask, stirring, completely dissolving, adding 1.5mmol of tert-butyl ethynyl disodium phosphate, stirring under reflux for reaction for 5.5 hours, cooling, filtering, concentrating the filtrate under reduced pressure, adding a proper amount of petroleum ether, filtering, and concentrating in vacuum to obtain the product with the yield of 80%.
Elemental analysis data: anal, calcd, for C42H27Cl12O3PSn2(%): c39.61, H2.14, Sn 18.64; found (%): c39.68, H2.29, Sn 18.73. Nuclear magnetic hydrogen spectrum data:1H NMR/δ1.34-1.68(9H),7.13-7.48(18H)。
example 3
Adding 3mmol of tris (2, 4-dichlorophenyl) tin chloride and 39mL of anhydrous acetonitrile into a 100mL round-bottom flask, stirring, completely dissolving, adding 1.5mmol of tert-butyl ethynyl disodium phosphate, stirring under reflux for reacting for 4 hours, cooling, filtering, concentrating the filtrate under reduced pressure, adding a proper amount of petroleum ether, filtering, and concentrating in vacuum to obtain the product with the yield of 77%.
Elemental analysis data: anal, calcd, for C42H27Cl12O3PSn2(%): c39.61, H2.14, Sn 18.64; found (%): c39.68, H2.29, Sn 18.73. Nuclear magnetic hydrogen spectrum data:1H NMR/δ1.34-1.68(9H),7.13-7.48(18H)。
example 4
Adding 3mmol of tris (2, 4-dichlorophenyl) tin chloride and 35mL of anhydrous toluene into a 100mL round bottom flask, stirring, completely dissolving, adding 1.5mmol of tert-butyl ethynyl disodium phosphate, stirring under reflux for reaction for 10 hours, cooling, filtering, concentrating the filtrate under reduced pressure, adding a proper amount of petroleum ether, filtering, and concentrating in vacuum to obtain the product with the yield of 58%.
Elemental analysis data: anal, calcd, for C42H27Cl12O3PSn2(%): c39.61, H2.14, Sn 18.64; found (%): c39.68, H2.29, Sn 18.73. Nuclear magnetic hydrogen spectrum data:1H NMR/δ1.34-1.68(9H),7.13-7.48(18H)。
example 5
Adding 3mmol of tris (2, 4-dichlorophenyl) tin chloride and 35mL of anhydrous methanol into a 100mL round-bottom flask, stirring, adding 1.5mmol of n-butyl ethynyl disodium phosphate after complete dissolution, stirring for reaction for 6 hours under reflux, cooling, filtering, concentrating the filtrate under reduced pressure, adding a proper amount of petroleum ether, filtering, and concentrating in vacuum to obtain a product, namely an n-butyl alkynyl substituted product, with the yield of 81%.
Example 6
Adding 3mmol of triphenyltin chloride and 35mL of anhydrous methanol into a 100mL round-bottom flask, stirring, completely dissolving, adding 1.5mmol of n-butyl ethynyl disodium phosphate, stirring under reflux for reacting for 6 hours, cooling, filtering, concentrating the filtrate under reduced pressure, adding a proper amount of petroleum ether, filtering, and concentrating in vacuum to obtain a product, namely a corresponding product of the triphenyltin, wherein the yield is 85%.
EXAMPLE 7 antitumor Activity test of Compounds
MCF-7, HT-29, A549 and HepG2 cells were obtained from American tissue culture Bank by culturing in culture medium containing 10% fetal bovine serum in the presence of CO2The culture was carried out at 37 ℃. The MTT method is used for detecting the proliferation and growth inhibition of the cells. The number of experimental cells was adjusted to obtain an absorbance at 570nm, the test drug solution (0.1nmol/L to 10. mu. mol/L) of the compound prepared in example 1 was set at 6 concentrations, and the cells were treated for 72 hours at each concentration for at least 3 parallel experiments and 3 replicatesVerification, determination of IC by statistical analysis50The value is obtained.
The compound prepared in example 1 was tested against tumor cells with cisplatin as a control: the in vitro growth inhibitory activity of MCF7 (human breast cancer cells), HT-29 (human colon cancer cells), A549 (human lung cancer cells) and HepG2 (liver cancer cells) is shown in Table 1 below. The compound is found to show stronger anticancer activity on the researched cells than cisplatin, especially has more obvious inhibition effect on A549, and can be used as a candidate anticancer compound.
TABLE 1
Figure BDA0001976280980000041

Claims (4)

1.一种具有抗肿瘤活性的炔基膦酸双芳基锡配合物,其特征在于,具有以下结构:(Ar3SnO)2P(O)R;其中,Ar为苯基、卤素或硝基取代的苯基;
Figure DEST_PATH_IMAGE001
且R2为C1-C6烷基。
1. A bisaryltin complex of alkynylphosphonate with antitumor activity, characterized in that it has the following structure: (Ar 3 SnO) 2 P(O)R; wherein, Ar is a phenyl group, a halogen or a nitrate substituted phenyl;
Figure DEST_PATH_IMAGE001
and R 2 is C1-C6 alkyl.
2.根据权利要求1所述的炔基膦酸双芳基锡配合物,其特征在于:Ar为苯基、4-氯苯基、2,4-二氯苯基;R2为叔丁基。2. alkynyl phosphonic acid bisaryl tin complex according to claim 1, is characterized in that: Ar is phenyl, 4-chlorophenyl, 2,4-dichlorophenyl; R 2 is tert-butyl . 3.权利要求1或2所述的炔基膦酸双芳基锡配合物用于制备抗癌药物。3. The alkynylphosphonic acid bisaryltin complex according to claim 1 or 2 is used for the preparation of anticancer drugs. 4.权利要求3所述的应用,其特征在于,癌症为子宫颈癌、乳腺癌、肺腺癌、肝癌、前列腺癌、结肠癌。4. The application of claim 3, wherein the cancer is cervical cancer, breast cancer, lung adenocarcinoma, liver cancer, prostate cancer, and colon cancer.
CN201910133828.7A 2019-02-22 2019-02-22 A kind of alkynylphosphonic acid bisaryltin complex with antitumor activity and its application Active CN109762016B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910133828.7A CN109762016B (en) 2019-02-22 2019-02-22 A kind of alkynylphosphonic acid bisaryltin complex with antitumor activity and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910133828.7A CN109762016B (en) 2019-02-22 2019-02-22 A kind of alkynylphosphonic acid bisaryltin complex with antitumor activity and its application

Publications (2)

Publication Number Publication Date
CN109762016A CN109762016A (en) 2019-05-17
CN109762016B true CN109762016B (en) 2021-03-16

Family

ID=66457138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910133828.7A Active CN109762016B (en) 2019-02-22 2019-02-22 A kind of alkynylphosphonic acid bisaryltin complex with antitumor activity and its application

Country Status (1)

Country Link
CN (1) CN109762016B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102471291A (en) * 2009-08-20 2012-05-23 拜尔农作物科学股份公司 3-triazolylphenyl-substituted sulfide derivatives for use as acaricides and insecticides
CN106336430A (en) * 2016-08-28 2017-01-18 衡阳师范学院 2-oxo-butyric acid p-methyl benzoyl hydrazone di-n-butyl tin complex and preparation method and application thereof
CN109069470A (en) * 2016-03-21 2018-12-21 杨宁荪 Use of specific benzodihydrofuran lignans for inhibiting breast cancer cell metastasis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004021A1 (en) * 2001-07-02 2003-01-16 Technion Research And Development Foundation Ltd. Method for the preparation of selectively-substituted corroles and new substituted corroles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102471291A (en) * 2009-08-20 2012-05-23 拜尔农作物科学股份公司 3-triazolylphenyl-substituted sulfide derivatives for use as acaricides and insecticides
CN109069470A (en) * 2016-03-21 2018-12-21 杨宁荪 Use of specific benzodihydrofuran lignans for inhibiting breast cancer cell metastasis
CN106336430A (en) * 2016-08-28 2017-01-18 衡阳师范学院 2-oxo-butyric acid p-methyl benzoyl hydrazone di-n-butyl tin complex and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"具有抗癌活性有机锡化合物的研究进展";陈绍文等;《聊城大学学报(自然科学版)》;20060930;第19卷(第3期);第50-52页 *
"双(三苯基锡)不饱和烃基膦酸酯的合成和性质";尹汉东等;《应用化学》;20010228;第18卷(第2期);第134页 *

Also Published As

Publication number Publication date
CN109762016A (en) 2019-05-17

Similar Documents

Publication Publication Date Title
Xu et al. Mitochondria-targeted half-sandwich ruthenium II diimine complexes: Anticancer and antimetastasis via ROS-mediated signalling
CN105237564A (en) 2-carbonyl-3-phenylpropionic acid salicylhydrazone bis(p-methylbenzyl)tin complex and preparation method and application thereof
CN103113420B (en) A kind of dibutyl tin oxygen duster compound containing ferrocenyl and preparation method and application
CN105237563A (en) 2-oxo propionic acid p-hydroxy benzoyl hydrazone bis(2,4-dichlorobenzyl) tin complex and preparation method and application thereof
CN102924528A (en) Anti-tumor bivalent platinum complex and preparation method for complex and ligand of complex
CN110713500A (en) Palladium complex with 2-benzoylpyridine thiosemicarbazide and its synthesis method
CN106432323A (en) 2-carbonyl butyric acid p-methoxy benzoyl hydrazone di-n-butyltin complex and preparation method and application thereof
CN105541898A (en) Benzoylhydrazone bis(p-methylbenzyl) tin 2-carbonyl-3-phenylpropionate complex, and preparation method and application thereof
CN109053612A (en) A kind of phenethyl replaces 1,3,5- compound in triazine class and its preparation method and application
CN103087115B (en) Ferrocenyl-containing tributyltin benzoate coordination polymer, and preparation method and application thereof
CN102942595A (en) Ruthenium complexes, preparation method thereof and application
CN104910212B (en) A kind of schiff bases platinum complex and its preparation method and application
CN109762016B (en) A kind of alkynylphosphonic acid bisaryltin complex with antitumor activity and its application
Rendon-Lopez et al. Ni (II), Pd (II) and Pt (II) complexes with SacNac tridentate ligand
CN107827934B (en) Tetravalent platinum complex with anticancer activity, preparation method and application
CN109762019B (en) A kind of alkynylphosphonate bisbenzyltin complex with antitumor activity
CN111333676A (en) Alkyl tin complex with antitumor activity and preparation method thereof
Gupta et al. Increasing the selectivity of biologically active tetranuclear arene ruthenium assemblies
US11787826B2 (en) Hydrocarbyl tin complex of alkynyl phosphonic acid with antitumor activity and application thereof
CN110698512B (en) Tin complex with 2-acetylpyridine thiosemicarbazide as ligand and its synthesis method
CN109694391B (en) Platinum complex taking 2-amino-5-chlorobenzophenone thiosemicarbazone as ligand and synthetic method and application thereof
CN113072593A (en) Metal organic iridium complex with anticancer activity and preparation method and application thereof
CN112661657A (en) Sertraline side chain amino structure derivative and preparation method and application thereof
CN106220669B (en) A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application
CN111925398B (en) FTO (fluorine-doped tin oxide) small-molecule inhibitor palladium complex and synthesis method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210210

Address after: 610000 Industrial Concentration Zone of Southwest Airport Economic Development Zone, Shuangliu District, Chengdu City, Sichuan Province

Applicant after: CHENGDU XINKE PHARMACEUTICAL Co.,Ltd.

Address before: 318001 room 627, A building, Grand Hyatt building, Jiaojiang District, Taizhou, Zhejiang.

Applicant before: TAIZHOU TAIJIE CHEMICAL TECHNOLOGY Co.,Ltd.

GR01 Patent grant
GR01 Patent grant